Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials.
about
Asymmetric dimethylarginine and reactive oxygen species: unwelcome twin visitors to the cardiovascular and kidney disease tablesAntiretrovirals induce endothelial dysfunction via an oxidant-dependent pathway and promote neointimal hyperplasiaFrom arginine methylation to ADMA: a novel mechanism with therapeutic potential in chronic lung diseasesRegulation of the ADMA-DDAH system in endothelial cells: a novel mechanism for the sterol response element binding proteins, SREBP1c and -2.Asymmetric dimethylarginine in angiotensin II-induced hypertensionAsymmetric dimethylarginine: a novel cardiovascular risk factor in end-stage renal disease.A systematic review of metabolite profiling in gestational diabetes mellitus.Effects of rosuvastatin on ADMA, rhokinase, NADPH oxidase, caveolin-1, hsp 90 and NFkB levels in a rat model of myocardial ischaemia-reperfusion.Asymmetric dimethylarginine induces endothelial nitric-oxide synthase mitochondrial redistribution through the nitration-mediated activation of Akt1Nitric oxide signaling in the microcirculation.Metabolomics reveals that tumor xenografts induce liver dysfunction.The relationship of nitric oxide synthesis capacity, oxidative stress, and albumin-to-creatinine ratio in black and white men: the SABPA studyEvaluation of asymmetric dimethylarginine (ADMA) levels in children with growth hormone deficiency.Asymmetric dimethylarginine: a novel biomarker of gastric mucosal injury?Novel cardiac-specific biomarkers and the cardiovascular continuum.Novel Risk Stratification Assays for Acute Coronary Syndrome.Metabolomic Profiling of Arginine Metabolome Links Altered Methylation to Chronic Kidney Disease Accelerated Atherosclerosis.Plasma asymmetric dimethylarginine levels are increased in neonates with bronchopulmonary dysplasia-associated pulmonary hypertensionProtective effect of CDP-choline on ischemia-reperfusion-induced myocardial tissue injury in rats.Comprehensive assessment of nephrotoxicity of intravenously administered sodium-oleate-coated ultra-small superparamagnetic iron oxide (USPIO) and titanium dioxide (TiO2) nanoparticles in rats.Asymmetric dimethylarginine in hematological malignancies: a preliminary study.The role of asymmetric dimethylarginine (ADMA) and leptin in hypertensive patients.Inhibition of human dimethylarginine dimethylaminohydrolase-1 by S-nitroso-L-homocysteine and hydrogen peroxide. Analysis, quantification, and implications for hyperhomocysteinemia.Anti-Atherogenic Activity of Polyphenol-Rich Extract from Bee Pollen.Biological variation of asymmetric dimethylarginine and related arginine metabolites and analytical performance goals for their measurement in human plasma.1H-NMR analysis of the human urinary metabolome in response to an 18-month multi-component exercise program and calcium–vitamin-D3 supplementation in older menSerum Asymmetric Dimethylarginine Concentrations in Two Models of Experimentally Induced Hypertension
P2860
Q26865426-478C9F9F-3C73-417D-86F9-972DC74B7A21Q30430542-C39CD5D1-6579-4BB5-8214-B9476A6D85FFQ33403876-C0D1154F-A385-4241-B373-F597F72C9D01Q33589158-CF966817-2733-424E-8EBE-D7F6C6D80BA3Q33728163-50A3C102-DFFC-41FE-9199-D9F0EBC78F31Q34201581-F14BDA4F-771D-4564-992D-CACDCA18E890Q34458995-D7F029BD-80E6-49EE-8E29-A1A95C644F72Q34562019-138F5999-FF40-4980-9DC7-CD0EC55AA93BQ36647252-765B5A0A-B328-46D0-8B52-37CBB84CFA91Q36717720-8E22AD18-33B7-4813-9C65-A9CD34D931AAQ37072851-ADE5910A-4B19-4655-8E9F-FCC2AC5F3499Q37219460-B975355E-DA55-40DF-B4E5-9A4CE6DFCDA3Q37702780-13970E67-7180-49CA-A4EC-474FFD85EC7EQ37883913-94609CE4-AB7A-42F2-95E3-22630BB198F2Q38009305-3E7F9269-49B9-4E2D-8A58-D79D08F44DC6Q38666324-D31F1A74-693F-4A67-A643-B517EDD2592FQ41979223-83335D3C-31B6-4259-9745-BF8FF5C45627Q42174480-7B183BC2-AA73-4F40-A082-0B28FF28C576Q42450274-7D2FDAD8-685B-452C-A1D5-1FD84E4F0F49Q43465717-83BB512D-2862-4BE4-9D89-79AB8AFAB3F1Q46216898-26F0384E-A23E-455A-96DC-6C91CD7EDC75Q46784655-105610E1-19CE-471E-9D4C-A812C344B5D7Q46982143-CB492B0D-0256-4BFB-BDDA-ECFAD55A892DQ47156005-0BD4C4E7-A9B8-46A5-A3B4-79F6A450F84DQ53021614-2E0610EC-57EC-4D2B-9C79-22A369D71565Q57834185-B0B81F55-2FFE-4583-9FDA-162864FB4730Q58996231-53A9052A-8156-4B81-9205-C18418E3E5EC
P2860
Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Asymmetric dimethylarginine (A ...... m prospective clinical trials.
@ast
Asymmetric dimethylarginine (A ...... m prospective clinical trials.
@en
type
label
Asymmetric dimethylarginine (A ...... m prospective clinical trials.
@ast
Asymmetric dimethylarginine (A ...... m prospective clinical trials.
@en
prefLabel
Asymmetric dimethylarginine (A ...... m prospective clinical trials.
@ast
Asymmetric dimethylarginine (A ...... m prospective clinical trials.
@en
P2860
P1433
P1476
Asymmetric dimethylarginine (A ...... m prospective clinical trials.
@en
P2093
Rainer H Böger
P2860
P304
P356
10.1191/1358863X05VM602OA
P478
10 Suppl 1
P577
2005-07-01T00:00:00Z